



To Whom It May Concern

June 17, 2025

NANO MRNA Co., Ltd.
Shiro Akinaga, President & CEO
(C o d e N o . 4 5 7 1)

**TUG1 ASO for glioblastoma
Phase 1 clinical trial reaches final dosing level**

We are pleased to announce that the investigator-initiated Phase 1 clinical trial of TUG1 ASO, an investigational drug in our pipeline, has moved to Level 4, the final dose, in patients with glioblastoma.

The trial was initiated in February 2024 at three institutes in Japan. Patient enrollment is progressing well and is expected to be completed by the end of 2025. Glioblastoma is the most malignant type of brain tumor, with 2000 new cases diagnosed in Japan per year. Currently, there is a strong need for new therapeutic agents since there are no treatment options available.

This trial is designed to evaluate the safety and tolerability of the TUG1 ASO and to determine the optimal dose for future trials. To date, a total of 12 patients have received the drug, and no major adverse effects have been reported. This trial will continue with safety as the highest priority.

In addition, we are actively pursuing out-licensing opportunities for TUG1 ASO in Japan and overseas. We are exhibiting at Bio International, which is currently being held in Boston, USA, from June 16-19.

<TUG1 ASO>

TUG1 is a long non-coding RNA that is not translated into protein, is overexpressed in many tumors including glioblastoma. It plays an important role in the survival of cancer cells. Professor Yutaka Kondo of Nagoya University, has elucidated the important role of TUG1 in the abnormal growth of cancer cells, thus, inhibiting TUG1 induces apoptosis to cancer cells. TUG1 ASO is a DDS formulation that uses a Y-shaped block co-polymer (YBC polymer), a DDS technology owned by NANO MRNA, as an ASO (antisense oligonucleotide) to inhibit TUG1.

Contact

Corporate Communication, NANO MRNA Co., Ltd.
info@nanomrna.co.jp